Poland develops its own TIL therapy for ovarian cancer

The National Cancer Institute in Warsaw has become the first in Poland to develop its own technology for manufacturing TIL therapy (tumor-infiltrating lymphocytes). The Chief Pharmaceutical Inspector has approved production of the TILANOCELL drug. The first application will be treating ovarian cancer — preparations are underway for a clinical trial to assess the method's safety.